Omega Therapeutics (OMGA)
(Delayed Data from NSDQ)
$1.85 USD
+0.06 (3.35%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $1.87 +0.02 (1.08%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Omega Therapeutics, Inc. [OMGA]
Reports for Purchase
Showing records 1 - 20 ( 38 total )
Company: Omega Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Updated MYCHELANGELO Data in Mid-2024; 1Q24 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Omega Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials; MYCHELANGELO Dose Escalation Data in Mid:24
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Omega Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Updated MYCHELANGELO Data Expected in Mid-2024; 4Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Omega Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q4/FY23 Financials; OTX-2002 Update Justifies Optimism
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Omega Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Research Collaboration With Obesity Leader Announced; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Omega Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Omega Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Omega Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Preclinical Evidence of OEC Efficacy in Fibrosis, Inflammation Shared at AASLD
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Omega Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Omega Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
EORTC-NCI-AACR 2023: Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Omega Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
OTX-2002 Yields Promising Initial MYCHELANGELO Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Omega Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Preliminary OTX-2002 Update Paints Pretty Picture: PK/PD Data Validating
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Omega Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Focus Remains on Initial MYCHELANGELO Data; 2Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Omega Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Omega Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Preclinical Data Supports OTX-2002 + Anti-PD1 Combo Activity; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Omega Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Initial MYCHELANGELO Data Near-Term; 1Q23 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Omega Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Omega Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Omega Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Omega Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
OTX-2002 Preliminary Data Release This Year; 2022 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R